Trastuzumab binds to the extracellular juxtamembrane domain of HER2 and inhibits the proliferation and survival of HER2-dependent tumors. It is approved by the Food and Drug Administration (FDA) for ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Outcomes in patients with hormone receptor–positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with ...
Please provide your email address to receive an email when new articles are posted on . Trastuzumab deruxtecan improved invasive DFS by 53% vs. T-DM1 for patients with residual disease after ...
A randomized, double-blind, three-arm, parallel group, phase 1 study to assess the pharmacokinetics, safety, and tolerability of PERT-IJS following a single dose of 420 mg intravenous infusion ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted priority review for trastuzumab deruxtecan in combination with pertuzumab for first-line ...
Trastuzumab deruxtecan (T-Dxd) is effective for HER2+ breast cancer but associated with ILD, necessitating careful monitoring and management. Studies show patients recovering from grade 1 ILD can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results